ArticleOral and maxillofacial surgery2026
Immunoexpression profile of LATS2 and YAP1 and its clinicopathological relevance in oral tongue squamous cell carcinoma.
Article in Oral and maxillofacial surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe objective of this study was to investigate the immunohistochemical expression of the Hippo pathway proteins LATS2 and YAP1 in oral tongue squamous cell carcinomas (OTSCCs) and normal oral mucosa (NOM), as well as potential relationships between them and clinicopathological characteristics and survival outcomes. MATERIALS AND
methodsTwenty-six cases of OTSCC and 8 samples of NOM were analyzed. Clinical data were obtained from medical records. Morphological assessment was based on the WHO (2005) grading system and the combined score of tumor cell nests (B) and tumor invasion depth (D) (BD model). Immunoexpression of LATS2 and YAP1 was determined by immunohistochemistry.
resultsIn NOMs, LATS2 expression was observed across all epithelial layers, with nuclear predominance, whereas YAP1 was observed in the basal and parabasal layers. YAP1 expression was significantly higher in OTSCCs (p < 0.001) and was significantly associated with the high-risk BD model (p = 0.034). OTSCCs with reduced LATS2 immunoexpression (p = 0.042) had poorer disease-free survival (DFS), while well-differentiated cases according to WHO presented better DFS outcome (p = 0.022). Multivariate analysis identified low LATS2 expression (HR 0.19; 95% CI 0.05–0.75; p = 0.017) and tumor size (HR 3.93; 95% CI 1.02–15.06; p = 0.046) as independent prognostic factors for 5-year DFS in OTSCC.
conclusionThe functional alterations of LATS2 and YAP1 may reflect the dysregulation of the Hippo pathway in OTSCC, which possibly influences mechanisms of tumor progression and clinical behavior in this carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.